Currently, the global pharmaceutical industry is undergoing three profound transformations: First, supply chain restructuring is accelerating. Escalating Sino-US trade friction, coupled with the EU’s Pharmaceutical Strategy 2030 systematically promoting domestic capacity building, is forcing global industrial chains to diversify away from single-source reliance. Second, technological revolutions are deepening through iterative advancements. New technologies like AI-driven drug design and synthetic biology are reshaping R&D and production paradigms, making digital and intelligent transformation the key to breaking through challenges. Third, demand structures are shifting dramatically, with pharmaceutical consumption growth in emerging markets (Latin America, Southeast Asia) far outpacing mature markets in Europe and the US, opening new blue oceans for Chinese innovative drugs and medical devices. Against this backdrop, the April 25, 2025 Central Political Bureau meeting first proposed “countering external uncertainties with the certainty of high-quality development,” charting a development path for innovative drug and device exports characterized by “innovation-driven, multi-faceted collaboration, and resilience-building foundations.”
Central Policy Direction:
Triple Breakthroughs from Strategic Blueprint to Industrial Practice
1. Digital and Intelligent Transformation: Rebuilding the Core Engine of Global Competitiveness
The Political Bureau meeting emphasized accelerating the “AI Plus” initiative. The seven-department “Implementation Plan for Digital and Intelligent Transformation of the Pharmaceutical Industry (2025–2030)” outlines a two-step goal: establishing over 100 digital and intelligent pharmaceutical and medical device factories by 2027, and achieving near-universal digital transformation among large-scale pharmaceutical enterprises by 2030. This strategy has already yielded results across the entire pharmaceutical value chain:
R&D: For instance, YingSi Intelligence’s self-developed Chemistry42 platform uses reinforcement learning algorithms to reduce lead compound optimization cycles by 78% to 4 months, saving over 30 million yuan per project in R&D costs. Hengrui Medicine’s R&D expenditure reached 1.533 billion yuan in Q1 2025, with cumulative R&D investment to date totaling 46 billion yuan. The company currently has over 90 independently developed innovative products in clinical development, with approximately 400 clinical trials underway domestically and internationally.
Production: For instance, Yangtze River Pharmaceutical Group actively leverages innovative applications of next-generation information technologies like AI, big data, and cloud computing to achieve intelligent management across the entire process—from cultivation and production to transportation. Digital and intelligent upgrades have boosted production efficiency by 28% and increased output by 43%. Fosun Xingmai has planned to establish seven AI-powered medical device product pipelines in Chongqing, supporting the development of “smart healthcare.”
Supply Chain: For instance, Jiuzhou Tong’s Chinese medicine traceability system was recognized as a national benchmark case for digital transformation. Its digital medical supply platform, Jiuzhou Wandi digital project, and Jiuxin Smart Traditional Chinese Medicine platform have all received national or provincial honors. Huahai Pharmaceutical has established a multi-channel marketing system in the U.S. market encompassing direct sales, major wholesalers, retail chains, and commercial companies. Its sales network covers most large and medium-sized pharmaceutical purchasers in the U.S., with key clients accounting for 95% of the U.S. generic drug market.
2. Market Diversification: A Strategic Choice to Overcome Geopolitical Barriers
The meeting emphasized “resolutely expanding high-level opening-up” and “coordinating domestic economic work with international economic and trade struggles.” Chinese pharmaceutical companies are pursuing a dual-track strategy of “deepening traditional markets while expanding into emerging markets”:
Belt and Road Initiative Emerges as Growth Pole: According to customs data compiled by the China Chamber of Commerce for Import and Export of Medicines and Health Products, from January to March 2025: Exports to the Arab League (22 countries) reached $1.08 billion, up 10.21% year-on-year.
Breaking into Developed Markets: For instance, Luye Pharma’s Rotigotine transdermal patch launched in the UK this year for treating signs and symptoms of early- and late-stage idiopathic Parkinson’s disease, as well as moderate-to-severe idiopathic restless legs syndrome. This product is the first generic version of Neupro® launched in the UK and is bioequivalent to Neupro®. Mindray Medical’s Q3 2024 report shows that its medical imaging business generated revenue of RMB 5.97 billion in the first three quarters, up 11.4% year-on-year, with the European market growing at over 30%.
3. Supply Chain Resilience: Fortifying the Foundational Logic of Industrial Security
In response to the U.S. “Critical Drug Supply Chain Reshoring” initiative, China is strengthening its “chain leader system” strategy:
API Upgrading: China holds a pivotal position in the global market for the production and supply of industrial-grade penicillin salt, vitamins, and sartan intermediates. Building on this foundation, the focus must shift toward extending into high-value API intermediates. For instance, Tonghe Pharmaceutical’s mesatazol potassium API has obtained Korean drug registration certification and completed submissions for six U.S./Canada filings. Jiuzhou Pharmaceutical’s peptide API facility in Suzhou will commence Phase II commercial capacity construction in 2025, with production expected to start in September 2025. Plans include establishing six peptide GMP production lines within five years to break the monopoly held by the U.S. and Europe.
Innovative Drugs and Medical Devices: Dual-Circulation Model – BeiGene’s Zebrutinib secured approval through simultaneous submissions in China and the U.S. In Q1-Q3 2024, U.S. revenue accounted for 73.5% of global sales, while domestic sales represented 10.5% of global revenue. MicroPort’s Firebird coronary stent has been implanted over 500,000 times in Belt and Road countries, while simultaneously introducing Israel’s Galmed NASH drug for clinical development in China, forming a closed-loop “technology introduction-transformation-export” model.
Addressing External Uncertainties:
Precision Alignment of Three Major Challenges and Countermeasures
1. Tariff Barriers and Technology Blockades: Shifting from ‘Cost Competition’ to ‘Value Breakthrough’
Premium Product Portfolio: Avoiding low-value-added “red ocean” products by focusing on emerging fields like biologics and cell therapies. For instance, CAR-T therapy production technologies (e.g., Legend Biotech’s CARVYKTI®) involve complex gene editing and cell culture processes, commanding higher value.
Leveraging Regional Free Trade Agreements: Facing U.S. market policy uncertainties, Chinese enterprises are adjusting strategies—particularly by accelerating Southeast Asian market expansion under RCEP origin accumulation rules while simultaneously building operations in emerging markets like Europe, the Middle East, and Latin America. Through regulatory approvals, channel development, and brand promotion, they are constructing more balanced global sales networks to effectively diversify operational risks.
2. International Regulatory Compliance: From ‘Passive Adaptation’ to ‘Rule Co-creation’
Breakthroughs in TCM Standard Internationalization: Taking the collaboration between the China Academy of Chinese Medical Sciences and the Guangxi Medicinal Plant Garden in assisting Laos with compiling the Lao Pharmacopoeia as an example, this partnership both respects local medicinal traditions and shares China’s practical experience. In Southeast Asia and Latin America, some countries have begun referencing standards for certain TCM varieties listed in the Chinese Pharmacopoeia based on practical needs. Canadian authorities have proactively engaged to promote recognition of Chinese medicinal species listed in Volume I of the Chinese Pharmacopoeia. These developments reflect international recognition of China’s pharmaceutical standards.
Building Full-Process Compliance Capabilities: For instance, WuXi AppTec’s two active pharmaceutical ingredient (API) manufacturing sites in Changzhou and Taixing, Jiangsu Province, both successfully passed U.S. Food and Drug Administration (FDA) inspections in March this year with zero defects. The FDA did not issue any Form 483 (inspection findings report).
3. Intellectual Property: From ‘Follow-on Innovation’ to ‘Original Research Leadership’
For instance, as of April 2025, Ascentage Pharma holds 541 authorized patents, including 379 overseas patents covering major global markets. Hengrui Medicine has filed 45 international patents in the PD-1 monoclonal antibody field, with its drug Camrelizumab entering markets like Turkey and Egypt through a “patent licensing + localized production” model.
Here’s the English translation of your text:
Deep Breakthroughs in High-Quality Development: From “Scale Expansion” to “Value Leadership”
1. Internationalization of Traditional Chinese Medicine: From “Cultural Export” to “Standards Export”
Policy synergy: The Implementation Plan for the Major Project of Revitalization and Development of Traditional Chinese Medicine specifies that during the 14th Five-Year Plan period, 50 overseas TCM centers will be established and 50 international standards will be released. The Ministry of Commerce’s “TCM Service Export Bases” have already covered 32 countries, serving more than 2 million people annually.
Technology-driven innovation: For example, Yunnan Baiyao has applied “phytochemistry-based metabolomics + network pharmacology” technology to increase the purity of the active ingredient Panax notoginseng saponins to 98%, thereby overcoming the EU’s “content uniformity” barrier for herbal medicine registration.
2. Global R&D Networks: From “Local Enterprises” to “Multinational Companies”
Rise of dual-headquarter models: For instance, BeiGene has established R&D centers in both China and the United States, conducting international multi-center Phase III clinical trials in parallel, achieving a “Shanghai by day, Boston by night” 24-hour relay R&D model. Similarly, Zai Lab has set up a translational medicine center in London to quickly access European clinical trial resources.
Cross-border innovation ecosystems: For example, Suzhou BioBAY has established offshore innovation centers in Singapore and Boston, creating a closed-loop model of “R&D overseas, translation in Suzhou, globalized markets.” It has already incubated more than 10 enterprises, including Innovent Biologics and Keymed Biosciences.
3. Green and Low-Carbon Transition: A New Threshold for Global Competition
Harbin Pharmaceutical Group (Hayao): In its 2025 Quality and Efficiency Enhancement with Sustainable Returns action plan, the company proposed to build a green industrial chain through digital-intelligent production and cost control. In April, Hayao’s subsidiary Sanjing Pharmaceutical signed an agreement with Jiuzhou Group for a distributed photovoltaic project in the Daqing Glass Industrial Park, aiming to accelerate its low-carbon transformation through solar power generation.
Qilu Pharmaceutical (Hainan) Co., Ltd.: Using the Qilu Pharmaceutical Integrated Energy Management Platform, its production workshop employs a three-stage heat exchange freeze dryer, saving over 200,000 kWh of electricity per unit annually. Meanwhile, its purified water preparation system has been upgraded with concentrated water recycling, raising the recovery rate to 90% and saving more than 10,000 tons of water annually.
Conclusion: Building New Advantages through Dynamic Balance
By consolidating innovation engines through digital-intelligent transformation, diversifying markets to spread risks, and strengthening supply chain resilience against shocks, China’s innovative pharmaceuticals and medical devices are shaping the “three certainties” of high-quality development to counter the “three uncertainties” of global industrial chain restructuring.
Facing multiple challenges of “tariff pressure + technological blockades + regulatory reshaping,” China’s pharmaceutical exports are shifting from “factor-driven” to “efficiency-driven” and “innovation-driven.” At the government level, it is necessary to accelerate the formulation of international TCM standards and improve policy toolkits for digital-intelligent transformation. At the enterprise level, companies should build resilient systems of “globalized R&D, localized production, and diversified markets.” At the industry level, it is essential to leverage new platforms such as free trade zones and cross-border innovation ecosystems to explore integrated export models of “medicine + services” and “products + technology.”
Going forward, only by rooting the “certainty” of high-quality development in innovation capacity, industrial resilience, and global collaboration can China firmly seize the strategic initiative of pharmaceutical and medical device internationalization amidst unprecedented global changes, contributing a “China Solution” to the global health industry chain.